SCHEMBL3539591

SCHEMBL3539591

CC(C)(C)OC(=O)c1cccc(N=C=S)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.45
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
GABRA5 P31644 1/20 0.41
GABRA6 Q16445 1/20 0.41
STAT3 P40763 1/20 0.38
MIF P14174 1/20 0.38
ABCB1 P08183 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
P2RY6 Q15077 2/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
RAD1 O60671 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5502036 0.87 SLC7A5 (0.46) SLC7A5GABRA1GABRG2GABRB3GABRA3
SCHEMBL1421363 0.83 ALDH1A1 (0.48) CA12CA1CA2CA9CA14
SCHEMBL29754225 0.83 ALDH1A1 (0.48) CA12CA1CA2CA9CA14
SCHEMBL30822881 0.81 SLC7A5 (0.49) SLC7A5GABRA1GABRG2GABRB3GABRA3
SCHEMBL2590530 0.81 CA1 (0.45) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL5558418 0.79 CYP4F2 (0.49) CA12CA1CA2CA9CA14
SCHEMBL110296 0.79 SLC7A5 (0.58) SLC7A5GABRA1GABRG2GABRB3GABRA3
SCHEMBL9953733 0.78 RAB9A (0.53) CA1CA2ALDH1A1MAPTMEN1
SCHEMBL2831122 0.78 ALDH1A1 (0.46) MIFP2RY6ALDH1A1MAPTALOX15
SCHEMBL28350987 0.77 SLC7A5 (0.56) SLC7A5GABRA1GABRG2GABRB3GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (WUXI) COMPANY, INC. (CN) 2016-09-01 US claimed
EP-3034076-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (Wuxi) COMPANY, Inc. (CN) 2016-06-22 EP claimed
EP-3446689-B1 ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA JC WUXI COMPANY INC (CN) 2025-01-08 EP disclosed
CN-113262218-B Use of isothiocyanate compounds 无锡杰西医药股份有限公司 2024-06-18 CN disclosed
CN-115429785-A Composition for improving bioavailability and treatment effect of isothiocyanate compounds 无锡杰西医药股份有限公司 2022-12-06 CN disclosed
US-11298334-B2 Use of isothiocyanate compounds JC (WUXI) COMPANY, INC. (CN) 2022-04-12 US disclosed
CN-104173272-B Sustained-release preparation of isothiocyanate compounds 无锡杰西医药股份有限公司 2021-07-06 CN disclosed
CN-104117064-B Combined application of isothiocyanate compounds and hormone drugs 无锡杰西医药股份有限公司 2021-02-26 CN disclosed
US-20190142780-A1 USE OF ISOTHIOCYANATE COMPOUNDS JC (WUXI) COMPANY, INC. (CN) 2019-05-16 US disclosed
US-10010520-B2 Combined application of isothiocyanate compound and anti-cancer medicine JC (WUXI) COMPANY, INC. (CN) 2018-07-03 US disclosed
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (WUXI) COMPANY, INC. (CN) 2016-09-01 US disclosed
US-20080306063-A1 PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS ARDEA BIOSCIENCES, INC. (US) 2008-12-11 US disclosed
US-7429667-B2 Phenylamino isothiazole carboxamidines as MEK inhibitors ARDEA BIOSCIENCES, INC. (US) 2008-09-30 US disclosed
US-7429667-B2 Phenylamino isothiazole carboxamidines as MEK inhibitors ARDEA BIOSCIENCES, INC. (US) 2008-09-30 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1438046-A4 THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE AGOURON PHARMA (US) 2004-10-20 EP disclosed
EP-1438046-A2 THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2004-07-21 EP disclosed
US-6720346-B2 (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS AGOURON PHARMACEUTICALS, INC. 2004-04-13 US disclosed
US-20030225147-A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use AGOURON PHARMACEUTICALS INC. 2003-12-04 US disclosed
WO-2003004467-A2 THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE CHUK, KIT, MKI67 SLC7A5 2073/4885GABRA1 3626/4885GABRG2 3964/4885
US-11298334-B2 Use of isothiocyanate compounds LIPC, CETP, LCAT SLC7A5 1101/4885GABRA1 4142/4885GABRG2 4232/4885
US-20080306063-A1 PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS BRAF, MAP4K2, MAP3K4 SLC7A5 2580/4885GABRA1 4091/4885GABRG2 4090/4885
US-20030225147-A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use TK1, MKI67, CDKN1A SLC7A5 516/4885GABRA1 1442/4885GABRG2 1878/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 SLC7A5 335/4885GABRA1 1161/4885GABRG2 1255/4885
US-20190142780-A1 USE OF ISOTHIOCYANATE COMPOUNDS LIPC, CETP, LCAT SLC7A5 1101/4885GABRA1 4142/4885GABRG2 4232/4885
US-10010520-B2 Combined application of isothiocyanate compound and anti-cancer medicine CHUK, KIT, MKI67 SLC7A5 2073/4885GABRA1 3626/4885GABRG2 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.